Recombinant SHP Substrate 1: A Versatile Research Tool for Immunoreceptor‑Signalling and Phosphatase‑Regulation Mechanistic Studies

Molecular Construct Design and Host‑Expression‑System Selection for SHP Substrate 1

Recombinant SHP Substrate 1 serves as an essential research reagent for dissecting SHP‑1/SHP‑2‑driven immune‑cell‑signal‑attenuation pathways. Most laboratory‑oriented constructs adopt truncated fragments covering intracellular residues 183‑268, containing functional ITIM (Y241) and ITSM (Y263) motifs to preserve full‑capacity SHP‑phosphase binding capability. Researchers deploy diverse fusion tags including GST, His6, FLAG and HA to satisfy distinct purification and pull‑down experimental workflows. X‑ray crystallography‑derived observations note that inserting 15‑20‑residue flexible GGGGS‑repeat linkers at the intracellular‑domain N‑terminus can substantially improve recombinant‑protein solubility and crystallization success rates. Specialized experimental objectives, such as palmitoylation‑modification profiling, demand constructs retaining the transmembrane segment spanning amino‑acid residues 160‑182.

Selection of expression host systems imposes measurable impacts upon final protein biochemical properties. E. coli BL21(DE3) strains deliver high volumetric yields ranging 50‑100 mg/L under optimized 0.1 mM IPTG 16 °C overnight‑induction conditions; co‑expressing chaperone plasmids such as pGro7 further promotes proper polypeptide folding, yet yields non‑post‑translationally‑modified protein material. Baculovirus‑driven Sf9 insect‑cell systems produce substrates carrying native‑like palmitoylation and glycosylation patterns with moderate yields of 5‑15 mg/L. HEK293F mammalian transient‑expression platforms generate recombinant protein most closely matching endogenous human molecular states at 10‑30 mg/L secretion‑level output. Comparative binding assays report 2‑3‑fold differences in SHP‑2‑affinity across hosts; mammalian‑derived material achieves KD values near 0.3 μM.

Optimized Purification Workflows and Multi‑Dimensional Quality‑Control Assessment

Purification pipelines are tailored according to the identity of fused affinity‑tag sequences. For GST‑tagged SHP Substrate 1, researchers perform glutathione‑agarose affinity capture, remove fusion segments via PreScission protease digestion, then apply Superdex 75 size‑exclusion chromatography to collect monodisperse protein fractions. His6‑tagged variants undergo Ni‑NTA‑resin enrichment and imidazole‑mediated elution, followed by buffer‑exchange steps for residual‑reductant elimination. Glycosylated construct preparations may incorporate Con A lectin‑affinity enrichment steps for selective glyco‑form enrichment. Maintaining 2‑5 mM β‑mercaptoethanol within process buffers protects disulfide‑bond integrity throughout multi‑step handling operations.

Finished lots routinely attain >95 % total protein purity with endotoxin levels kept below 0.1 EU/μg to satisfy cell‑culture‑experiment requirements. Dynamic‑light‑scattering measurements report polydispersity‑index values below 0.2 and hydrodynamic‑radius readings around 3.2 nm for monodisperse protein dissolved inside physiological‑composition buffers. Functional‑validation workflows include in‑vitro Lyn‑kinase‑mediated tyrosine‑phosphorylation, mass‑spectrometric mapping of Y241/Y263 modification‑sites, SPR‑based SHP‑2‑affinity‑measurement (expected KD 0.5‑2 μM), and phosphatase‑activity‑read‑out assays recording 2‑3‑fold SHP‑2‑catalytic‑rate enhancement. Batch‑to‑batch variation for phosphorylation‑efficiency is confined within 15 %, while overall biological‑activity deviation remains below 20 %. Properly glycerol‑supplemented samples retain stable functional performance for more than two‑years stored at −80 °C.

Molecular‑Mechanistic Insights Into SHP‑2 Activation Triggered by Phosphorylated SHP Substrate 1

Phosphorylated SHP Substrate 1 modulates SHP‑2 catalytic function through two synergistic molecular mechanisms. Binding events relieve SHP‑2 auto‑inhibitory conformational restraints by displacing the N‑SH2 domain away from the enzyme catalytic cleft, while simultaneously elevating substrate‑recognition‑affinity. Unphosphorylated SHP‑2 displays baseline KD near 8 μM; interaction with dual‑phosphorylated (Y241 + Y263) SHP Substrate 1 reduces KD down to approximately 0.5 μM and improves kcat/Km catalytic‑efficiency metrics by 50‑100‑fold under pH 7.0 and 25 °C assay‑conditions. Dual‑site phosphorylated substrate produces 3‑5‑fold stronger activation responses compared with single‑site phosphorylated peptide counterparts, reproducing cooperative signal‑amplification phenomena observable within intact cellular‑signalling networks.

Co‑crystal structural datasets (PDB 6N6F) demonstrate how phosphorylated SHP Substrate 1 peptide moieties drive SHP‑2 domain‑rearrangement, opening the catalytic cleft by 15‑degrees to permit substrate‑polypeptide ingress. Further nanodisc‑reconstituted biochemical assays confirm membrane‑anchored SHP Substrate 1 exhibits augmented inhibitory potency toward TCR‑signalling cascades. In‑vitro reconstitution experiments mixing phosphorylated substrate together with purified ZAP70, LAT and SLP76 signal‑transduction components achieve >70 % reduction of ZAP70 kinase‑activity via SHP‑2‑dependent de‑phosphorylation. SPR‑derived kinetic‑profiling documents that SHP‑2‑substrate complexes display 10‑20‑fold binding preference toward ZAP70 Y492 phospho‑peptide relative to alternative tyrosine‑phosphorylated sequence motifs. A distinct concentration‑threshold‑dependent‑effect exists; local substrate concentrations above 10 μM are required for robust inhibitory‑signal‑complex assembly within synthetic‑biochemical systems.

Multi‑Layered Interaction‑Network Mapping and Diverse Basic‑Research‑Oriented Application Scenarios

Affinity‑purification coupled with mass‑spectrometry proteomic workflows have identified over forty distinct protein partners associating with phosphorylated SHP Substrate 1. These interaction partners contain adaptor‑family molecules (Grb2, Gads), Src‑type kinases (Lyn, Fyn), and protein‑tyrosine‑phosphatase‑family members (SHP‑1, SHP‑2). Multiple binding events occur at spatially segregated polypeptide‑regions: Grb2 SH3‑domains engage PxxP proline‑rich segments, whereas 14‑3‑3 protein‑modules interact with phosphorylated Ser215 residues. Certain molecular contacts exhibit strict post‑translational‑modification dependence; ubiquitin‑ligase Cbl exclusively binds de‑phosphorylated SHP Substrate 1 copies, mediating dynamic signal‑complex assembly‑disassembly cycles. Hydrogen‑deuterium‑exchange mass‑spectrometry captures long‑range allosteric conformational perturbations propagating as far as 3 nm across SHP‑2 domain architecture upon substrate‑ligand engagement.

Recombinant SHP Substrate 1 material enables diverse exploratory‑research workflows spanning drug‑candidate screening, structural biology and immune‑cell‑engineering assignments. High‑throughput phosphatase‑assay and AlphaScreen‑based competition‑binding systems support large‑compound‑library screening campaigns targeting SHP‑2‑SHP‑Substrate‑1 protein‑protein‑interaction interfaces. X‑ray crystallography and cryo‑EM structural studies rely on high‑quality recombinant substrate material to resolve multi‑protein‑complex atomic‑level architectures. In immunology‑oriented cell‑model research, substrate constructs assist CAR‑T‑engineering, regulatory‑T‑cell‑differentiation and CRISPR‑gene‑editing‑effect‑validation laboratory‑projects.

Phospho‑SHP‑2 Targeted Antibody Reagents from ANT BIO PTE. LTD

ANT BIO PTE. LTD provides phospho‑SHP‑2‑specific antibody research reagents supporting SHP‑1/SHP‑2‑centered immune‑signal‑transduction mechanistic basic‑research projects. Each antibody lot undergoes peptide‑array‑based epitope‑specificity screening and multi‑assay functional‑validation prior to commercial‑product release.

Catalog Table of Phospho‑SHP‑2 Research Antibody Reagents

Functional‑Validation Characteristics of ANT BIO PTE. LTD Phospho‑SHP‑2 Antibody Reagents

S0B1093 recombinant‑rabbit‑monoclonal‑antibody selectively recognizes SHP‑2 phosphorylated Tyr542 epitope with minimal cross‑reactivity to unmodified SHP‑2 polypeptide chains. S0G0015 antibody‑duo kit supplies matched detection‑reagent combinations to streamline experimental setup. Validated sample matrices encompass immune‑cell lysates, in‑vitro kinase‑reaction products and recombinant‑protein biochemical‑assay specimens. Qualified experimental workflows include Western‑blot phospho‑protein quantification, immunoprecipitation, and cell‑lysate‑based immuno‑detection supporting SHP‑2‑activation‑state monitoring in SHP Substrate 1 reconstituted biochemical‑systems.

Core Fundamental‑Research Applications for Phospho‑SHP‑2 Antibody Panel

1. Western‑blot monitoring of SHP‑2 Tyr542 phosphorylation‑activation status within SHP Substrate 1 re‑constituted in‑vitro biochemical‑assay‑systems

2. Immunoprecipitation‑based capture of activated SHP‑2 complexes for downstream proteomic‑interaction‑network identification experiments

3. Cell‑model‑based signal‑transduction research quantifying SHP‑2‑activation‑dynamics downstream of immunoreceptor‑stimulation events

4. Biochemical‑compound‑screening workflows assessing small‑molecule modulator influences over SHP‑2‑phosphorylation‑activation responses

5. Orthogonal read‑out assays complementing SPR‑binding‑kinetics measurements investigating SHP‑Substrate‑1‑SHP‑2 molecular‑interaction‑characteristics

6. Mechanistic‑phenotyping for gene‑knockout / over‑expression cell‑lines interrogating immune‑receptor‑inhibitory‑signalling‑cascade outputs

Global Manufacturing & Compliance Standards

All phospho‑SHP‑2 antibody batches complete peptide‑epitope‑specificity profiling and multi‑platform functional‑performance‑verification before commercial‑product release. Manufacturing facilities adhere to ISO9001, ISO13485 and EU 98/79/EC certification specifications governing life‑science‑research‑reagent‑production‑protocols. In‑house application‑science teams supply detailed immuno‑assay‑SOP‑documents and curated SHP‑phosphatase‑immune‑signalling‑reference‑publication‑resources. The broader reagent ecosystem includes recombinant‑proteins, PTM‑detection‑antibodies and ELISA‑kits supporting comprehensive immunology multi‑omics‑research pipelines.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANT BIO PTE. LTD., we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.